Abstract-Granulocyte-colony stimulating factor
INTRODUCTION
Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic growth factor which plays important roles in proliferation and differentiation of myeloid cells. In recent years, various experimental studies have shown that G-CSF has protective effects on many neurological diseases, such as stroke, Parkinson's disease, amyotrophic lateral sclerosis, etc. (Meuer et al., 2006; Popa-Wagner et al., 2010; Pollari et al., 2011) . There is sufficient evidence on its neuroprotective effects on cerebral ischemic models. Apart from promoting stem cell mobilization and targeting to brain, apoptosis reduction and inflammation inhibition in acute phase as well as neurogenesis promotion and angiogenesis enhancement in chronic phase were also indicated as playing a role (Solaroglu et al., 2006; Zhao et al., 2006; Sehara et al., 2007; Popa-Wagner et al., 2010; Sugiyama et al., 2011) . But as to intracerebral hemorrhage (ICH), another type of stroke, few studies have been conducted. The key hemorrhagic damages are perihematomal tissue injuries, the main manifestations of which are formation of brain edema, disruption of blood-brain barrier (BBB), cell death and apoptosis, etc. caused by substances from central nervous system (CNS) cells disruption and red blood cells lysis. It was found that G-CSF decreased perihematomal brain edema, BBB permeability and numbers of apoptotic cells (Park et al., 2005) . However, the effects were only observed on isolated time points without dynamic observation and the involved mechanisms remain unknown.
Aquaporin-4 (AQP4), as the most abundant water channel in CNS, mainly plays an important role in formation and resolution of brain edema. Previous work from our group indicated that AQP4 knock-out aggravated brain edema, worsened neurological deficits and increased cell injuries after ICH, suggesting AQP4 had positive effects on ICH (Tang et al., 2010) . Vascular endothelial growth factor (VEGF) is another important factor that has protective effects on many neurological diseases by acting on neurons and glial cells. Our previous research demonstrated that VEGF alleviated perihematomal tissue injuries by reducing brain edema, neuronal death and neurological deficits (Chu et al., 2013) .
The main pathway activated by G-CSF to elicit biological effects is Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway (Harada et al., 2005) . In addition, G-CSF can also activate phosphatidylinositol 3 0 -kinase (PI3K)/Akt and mitogenactivated protein kinase (MAPK) pathways, including extracellular signal-regulated kinase (ERK), C-Jun amino-terminal kinase (JNK) and p38-MAPK pathways (Carvalho et al., 2011) . Interestingly, VEGF can also be up-regulated via JAK/STAT3 pathway (Loeffler et al., 2005) . One study demonstrated G-CSF increased VEGF and its receptor depending on JAK/STAT pathway (Jung et al., 2006) . Besides, the inhibitors of MAPKs suppressed AQP4 up-regulation induced by manganese-treatment or oxygen-glucose deprivation and recovery (Rao et al., 2010; Qi et al., 2011) . Based on the above evidences that G-CSF is closely related with VEGF and AQP4, both of which are essential to perihematomal tissue injuries, we speculate that the effects of G-CSF on ICH may result from regulating VEGF and AQP4 expression via certain pathways.
To test these hypotheses, we injected G-CSF intraperitoneally after ICH and examined the changes of perihematomal tissue injuries and expression of VEGF and AQP4 in wild-type (AQP4 +/+ ) mice. We also investigated whether effects of G-CSF were VEGF and AQP4 dependent using VEGF receptor (VEGFR) inhibitor and AQP4 knock-out (AQP4 À/À ) mice. Furthermore, we examined which signal transduction pathways could be activated by G-CSF to regulate VEGF and AQP4 expression through astrocyte cultures.
EXPERIMENTAL PROCEDURES Animals and experimental groups

Male AQP4
+/+ and AQP4 À/À mice, 3-4 month-old, weighing 25-33 g, were kindly provided by Doctor Hu, Jiangsu Key Laboratory of Neurodegeneration, Department of Anatomy, Histology and Pharmacology of Nanjing Medical University in China. Mice were kept in the environment of a 12-h-light/dark cycle with free access to food and water. Our animal studies and protocols were approved by the Institutional Animal Care and Use Committee of Fudan University. AQP4 +/+ mice were randomly divided into six groups: Group 1: Control. Group 2: Control plus G-CSF. Group 3: Sham operation. Group 4: ICH. Group 5: ICH plus G-CSF.
Group 6: ICH plus G-CSF plus SU5416, a VEGFR-2 inhibitor. Groups of AQP4 À/À mice were the same as AQP4 +/+ mice except absence of Group 6. The parameters were measured at 1, 3 and 7 days after operation and each parameter of each group contained six mice.
Mouse ICH model and drugs injection
Mice were anesthetized with 10% chloralhydrate (350 mg/ kg) and were placed in a stereotaxic frame (Alcott Biotech, Shanghai, China). Through a hole drilled in the skull, a 32-gauge needle was implanted into the striatum, 2.0 mm lateral to the midline, 1.0 mm anterior to the coronal suture and at a depth of 4.0 mm from the surface of the brain. Each mouse was microinjected with 5 ll of autologous whole blood (right striatum) taken from the tail vein over 10 min using a 5-ll microinfusion pump (ALC-IP600, Alcott Biotech). Then the needle was pulled out without blood reflux after 5 min dwelling and the wound was sutured. Only the mouse with neurological deficit was regarded as a successful model. The mice in sham operation group had the same operation but no blood was injected. According to previous studies (Park et al., 2005) and our preliminary experiment (four doses: 5, 15, 50 and 150 lg/kg), recombinant human G-CSF (rhG-CSF, Millipore, Billerica, MA, USA) was injected intraperitoneally with a dose of 50 lg/kg at 2 h after ICH induction and daily afterward for 7 days. SU5416 (60 lg/ kg Sigma-Aldrich, St. Louis, MO, USA) was injected intracerebroventricularly (0.9 mm lateral to the midline, 0.1 mm posterior to the coronal suture and at a depth of 3.1 mm from the surface of the brain) immediately after ICH (Lee and Agoston, 2010) . The same dose of normal saline was injected intraperitoneally as control.
Astrocyte culture and groups
Astrocyte culture was prepared as previously reported (Yang et al., 2008) . Cerebral cortices from neonatal Sprague-Dawley rat brains were removed and carefully dissected. The tissue was dissociated in Dulbecco's Modified Eagle Medium (DMEM) containing 0.0025% trypsin/EDTA (Gibco, Carlsbad, CA, USA) and passed through a 70-mm pore nylon mesh. After centrifugation, the cell pellet was resuspended in DMEM/F12 medium containing 10% fetal bovine serum (FBS), 50 U/ml penicillin, and 50 mg/ml streptomycin (all from Gibco), and then plated onto 25-ml tissue culture flasks. The medium was renewed every 2-3 days. After incubation for 5-7 days, the cells were trypsinized and subcultured in 60-mm diameter culture dishes. The cell population consisted of over 95% astrocytes as determined by immunocytochemical staining with anti-glial fibrillary acidic protein (GFAP) antibody (Millipore). The astrocytes were randomly divided into seven groups. Group 1: Normal astrocytes. Group 2: G-CSF (100 ng/ml). Group 3: G-CSF plus U0126 (10 lmol/L, Invivogen, San Diego, CA, USA), an ERK inhibitor. a PI3K inhibitor. The doses of drugs were according to our preliminary experiment (four doses of rhG-CSF: 10, 50, 100 and 250 ng/ml) and previous reports (Habas et al., 2006; Kawasaki et al., 2007; Sinke et al., 2008; Kojima et al., 2011) .
Neurological testing
A standardized battery of behavioral tests was used to quantify sensorimotor neurological function at 1, 3 and 7 days after first injection. The battery consisted of two tests: the postural reflex test, which examines upperbody posture while the animal was suspended by the tail, and the forelimb placing test, which examines sensorimotor integration in forelimb placing responses to visual, tactile, and proprioceptive stimuli. Neurological function was graded on a scale of 0-12 (normal score 0, maximal score 12) as previously described (Belayev et al., 2003) . Tests were conducted by an observer blinded to the treatment group.
Brain water content
Brain was rapidly removed from the skull at 1, 3 and 7 days after operation and the olfactory bulbs and brain stem with the cerebellum were eliminated before water contents were measured, which were performed less than 2 min after the decapitation. After the wet weight of ipsilateral (hemorrhage) hemisphere was measured, the tissue was then dried at 100°C for 24 h, and its dry weight was measured. Brain water content (as a percentage) = (wet weight À dry weight)/wet weight Â 100% (Agrawal et al., 1968) .
Brain specific gravity
For determination of specific gravity, a linear kerosene/ brombenzene gradient was prepared. Appropriate volumes of two stock solutions with a specific gravity of SG = 0.9750 g/cm 3 and SG = 1.0650 g/cm 3 were mixed with a gradient mixer (LKB Ultrograd 11300). The outflow of the mixer was connected to a graded cylinder containing a volume of 100 ml. During the filling process the cylinder was lowered to maintain a steady flow to the surface of the gradient. The cylinder, the connecting tubes, and the beakers containing the stock solutions were kept at a constant temperature of 25°C in a heated water bath. After 12 h the gradient was calibrated with 5-ll droplets of potassium sulfate solutions with specific calculated gravities of 1.0250, 1.0300, 1.0400 and 1.0450 g/cm 3 , respectively. After removing, the brain was cut into a 2-mm slice with the center as needle entry point. Six tissue samples surrounding hematoma were removed from the slice with Pasteur pipettes of 3-mm diameter. The samples were immersed into the gradient, and the specific gravity was read from the column exactly 90 s later (Tang et al., 2010) .
Determination of BBB permeability with the use of Evans Blue
Evans Blue (EB, Sigma-Aldrich) in normal saline (2%, 4 ml/kg) was injected intravenously at 1, 3 and 7 days after operation. The mice were anesthetized 1 h later and perfused with 200 ml of normal saline solution through the left cardiac ventricle. They were decapitated and the tissue samples surrounding hematoma were obtained as mentioned above. The samples were homogenized in methylformamide (1 ml/100 mg brain tissue), incubated for 24 h at 60°C, and centrifuged for 5 min at 1000g. The absorbance (A) of supernatants was analyzed at 632 nm by spectrophotometry. The amount of EB (lg/g) was calculated through standard curve established by known concentrations of EB.
ELISA for VEGF protein expression
VEGF protein levels were measured using mouse VEGF enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN, USA). Sample homogenates and culture supernatants preparation and assays were performed as recommended by the manufacturer. The protein levels of VEGF in brain tissues were normalized and expressed as pg per mg of total protein.
Western blotting
Protein extraction: (1) In vivo experiment: Brain hemispheres (hemorrhage) were homogenized in RIPA lysis buffer (Beyotime, Suzhou, China) and 1 mmol/L phenylmethanesulfonyl fluoride (PMSF). (2) In vitro experiment: The culture fluid of each group of astrocytes was discarded 48 h after drugs administration and the cells were treated with RIPA lysis buffer and PMSF. Additionally, astrocytes of Group 2 were treated in the same way at 0, 12, 24, 48 and 72 h after drugs administration. After centrifugation, the supernatant was used for analysis. Proteins (50 lg) were loaded onto 4% stacking/12% separating sodium dodecyl sulfate (SDS)-polyacrylamide gels for electrophoresis, and then transferred onto nitrocellulose transfer membranes. After blocking, membranes were incubated overnight at 4°C with anti-AQP4 (1:1000, Sigma-Aldrich), anti-p-JNK (1:1000, CST, Boston, MA, USA), anti-p-ERK (1:1000, CST), anti-p-p38 (1:1000, CST), anti-p-STAT3 (1:1000, CST), and anti-p-Akt (1:1000, CST) rabbit polyclonal antibodies. Membranes were then incubated for 1 h at room temperature with horseradish peroxidase (HRP) labeled goat anti-rabbit secondary antibody (1:4000, Vector, Burlingame, CA, USA). The membranes were placed into ECL solution for 5 min, and then exposed. The intensity of blots was quantified using the Leica Image Processing and Analysis System. b-Actin was used as an internal control.
Immunofluorescence
Specimen preparation: (1) In vivo experiment: AQP4 +/+ mice were anesthetized at 1, 3 and 7 days after operation and perfused with normal saline solution and 4% ice-cold paraformaldehyde through the left cardiac ventricle. Brain tissues were removed and gradient dehydrated. Serial coronal sections (10 lm) were then cut on a freezing microtome (CM 1900, Leica, Wetzlar, Germany) . (2) In vitro experiment: The coverslips full of astrocytes were taken out at 48 h after drugs administration. Each group of astrocytes was fixed by 4% paraformaldehyde for 30 min. After washing, the sections were blocked by 10% goat serum. Sections were incubated overnight at 4°C with anti-AQP4 rabbit polyclonal antibody (1:500, Sigma-Aldrich), and then incubated 1 h at 37°C with fluorescein isothiocyanate (FITC) coupled secondary goat anti-rabbit immunoglobulin G (IgG) (1:500, Invitrogen). The astrocytes were also stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) for highlighting the nuclei.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining
Mice were treated as in ''immunofluorescence'' part to obtain brain sections. After washing, the sections were stained for TUNEL using In Situ Cell Death Detection Kit (Roche, Mannheim, Germany), following the protocol provided by the manufacturer. Sections were also stained with DAPI for highlighting the nuclei.
Nissl staining
Brain frozen sections were obtained by method in ''immunofluorescence'' part. Sections were stained with Toluidine Blue (Sigma-Aldrich) for 20 min. After washing by distilled water, sections were separated by color with 95% ethanol for 30 s.
Cell counting
For determining cell counts, coronal sections of 10 lm were cut from the optic nerve to mamillary body. Every other section was chosen after the needle entry site was first spotted. The brain sections through the needle entry site starting with the first appearance of TUNEL or Nissl staining cells, extending to the most caudal parts of the hematoma zone were TUNEL or Nissl staining at 1, 3 and 7 days after operation (n = 6 per group). Six brain sections per mouse were selected according to the principle that it provides most variability in TUNEL or Nissl staining when compared to control group. Mean number of positive cells per section was recorded.
Statistical analysis
All data were presented as mean ± standard error of mean (SEM) and analyzed with SPSS12.0. Differences between groups were compared by using a one-way analysis of variance (ANOVA). When the ANOVA identified significant between-group differences, Tukey's honestly significant difference (HSD) tests were used for intergroup comparisons. Two-tailed Student t tests were for comparisons between AQP4 +/+ and AQP4 À/À mice in each group. In addition, we added a two-way ANOVA with replication in sections containing AQP4 +/+ and AQP4 À/À mice to examine whether interactions existed between G-CSF injection and presence of AQP4 gene.
RESULTS
Effects of different doses of G-CSF in in vivo and in vitro experiments
We used four doses of rhG-CSF from low to high to determine the optimal one. We found rhG-CSF of 5 mg/ kg had no effects and 15 mg/kg only reduced brain edema at 1 day and alleviated neurological deficits at 7 days after ICH as well as up-regulated AQP4 at each time point and VEGF at 1 day (p < 0.05). Both doses of 50 and 150 mg/kg developed more protective effects and higher levels of AQP4 and VEGF proteins than another two doses (p < 0.05). So we chose 50 mg/kg in our subsequent experiments. In in vitro experiment, low dose did not have any effects. Another three doses of rhG-CSF up-regulated VEGF and AQP4 expression and levels of the two proteins were higher in doses of 100 and 250 ng/ml (p < 0.05). So we selected 100 ng/ml as experimental dose (Fig. 1) .
Expression of AQP4 protein in each group of AQP4 +/+ mice
Immunofluorescence showed the AQP4 staining was vascular based on structure with green fluorescence and abundantly expressed in groups of control plus G-CSF, ICH, ICH plus G-CSF and ICH plus G-CSF plus SU5416 at each time point after operation. Meanwhile, both Western blot and immunofluorescence revealed an increase of AQP4 protein at striatum after 1, 3 and 7 days by intraperitoneal rhG-CSF injection in normal mice (p < 0.05). Furthermore, perihematomal AQP4 protein expression was increased by rhG-CSF at the three time points after ICH, which was not changed by intracerebroventricular injection of SU5416. The statistical differences were found in semi-quantitative analysis of Western blot (p < 0.05) (Figs. 2, 3A, B) .
Expression of VEGF and its receptors in each group of AQP4
+/+ mice ELISA showed intraperitoneal rhG-CSF injection upregulated VEGF protein expression at striatum of normal mice at all time points. Meanwhile, perihematomal VEGF protein expression (pg per mg of total protein) was increased by rhG-CSF at 1, 3 and 7 days (p < 0.05) after ICH, which was not influenced by intracerebroventricular SU5416 injection (Fig. 3E) . VEGF has two main receptors: VEGFR-1, also called fams-like tyrosine kinase-1 (Flt-1) and VEGFR-2, also called fetal liver kinase-1 (Flk-1). There was no effect of rhG-CSF on Flt-1 expression whether at normal state or after ICH. However, intraperitoneal injection of rhG-CSF significantly increased Flk-1 expression both at normal state and after ICH at the three time points (p < 0.05) (Fig. 3C, D) .
Brain water content, brain specific gravity and EB extravasation amount of AQP4 +/+ and AQP4 À/À mice Brain water content and brain specific gravity are two methods for measuring perihematomal brain edema, and the main advantage of the latter is the possibility to obtain reliable results in small brain tissues. Expectably, the results were consistent with each other. Since we focused on perihematomal brain edema, we chose brain tissues also surrounding hematoma for investigating VEGF's effect on BBB permeability. RhG-CSF had no effect on normal mice in these sections. Injection of rhG-CSF intraperitoneally reduced brain edema and EB extravasation surrounding hematoma in both types of mice at 1, 3 and 7 days after ICH (p < 0.05), but the injuries were more severe in AQP4 À/À mice than AQP4 +/+ mice in both ICH and ICH plus G-CSF groups (p < 0.05) (Fig. 4A-C) . Intracerebroventricular injection of SU5416 weakened but not counteracted G-CSF's effect on brain edema, while effect of G-CSF on BBB permeability remained unchanged (p < 0.05) (Fig. 5A-C) . To investigate whether these effects of G-CSF had something to do with AQP4, we studied the interactions between G-CSF injection and presence of AQP4 gene by a two-way ANOVA with replication. The F (p) values were 5.21 (0.033), 4.86 (0.039) and 6.77 (0.017) (brain water content); 4.60 (0.044), 4.83 (0.039) and 5.29 (0.032) (brain specific gravity); 6.13 (0.022), 5.61 (0.040) and 6.33 (0.020) (EB), suggesting presence of interactions.
Neurological scores of AQP4
+/+ and AQP4 À/À mice There was no influence of rhG-CSF on normal mice in this section. Meanwhile, more severe neurological deficits were found in AQP4 À/À mice than AQP4 +/+ mice at 1, 3 and 7 days after ICH (p < 0.05). Injection of rhG-CSF Fig. 1 . Results of our preliminary experiment. Intraperitoneal rhG-CSF injection of 5 mg/kg had no effects while 15 mg/kg alleviated brain edema at 1 day and neurological deficits at 7 days after ICH as well as up-regulated AQP4 at each time point and VEGF at 1 day (n = 6, ⁄ p < 0.05 vs. ICH). There were less brain water content, neurological scores and higher levels of AQP4 and VEGF proteins in groups of 50 and 150 mg/kg than another two doses (n = 6, # p < 0.05 vs. groups of ICH, 5 and 15 mg/kg). In cultured astrocytes, rhG-CSF administration of 10 ng/ml did not make any change and 50 ng/ml increased VEGF and AQP4 expression from 24 h (n = 6, ⁄ p < 0.05 vs. 0 h). Higher levels of VEGF and AQP4 proteins were found at 12 h after rhG-CSF administration and lasted within 72 h in groups of 100 and 250 ng/ml (n = 6, # p < 0.05 vs.0 h and groups of 10 and 50 ng/ml). intraperitoneally alleviated neurological deficits in both types of mice (p < 0.05), while the neurological functions were still better in AQP4 +/+ mice (p < 0.05) (Fig. 4D) . SU5416 attenuated but did not counteract the protective effect of G-CSF (Fig. 5D) ( Fig. 4E, F) . These effects of G-CSF still existed but were attenuated after injection of SU5416 (p < 0.05) (Fig. 5E,  F) . Similarly, a two-way ANOVA with replication showed F values were 5. 04, 5.04, 5.27 and 6.91, 5.39, 5 .29 with the corresponding p values of 0.036, 0.036, 0.033 and 0.016, 0.031, 0.032, suggesting interactions between G-CSF administration and presence of AQP4 gene existed.
Expression of phosphorylation of MAPKs, STAT3 and Akt by G-CSF in cultured astrocytes
Western blot including semi-quantitative analysis showed that in cultured astrocytes, p-ERK and p-STAT3 were up-regulated at 12 h after rhG-CSF administration and peaked at 48 h (p < 0.05). While no up-regulation of p-p38, p-JNK or p-Akt was observed within 72 h after rhG-CSF administration. Meanwhile, expression of VEGF and AQP4 proteins was increased by rhG-CSF after 12 h and peaked at 48 h (p < 0.05), in accord with the changing trend of p-ERK and p-STAT3 (Fig. 8) .
Expression of AQP4 and VEGF proteins in each group of cultured astrocytes
Since AQP4, VEGF, p-ERK and p-STAT3 all peaked at 48 h after rhG-CSF administration, we selected this time point in this section. ELISA showed that up-regulation of VEGF by rhG-CSF was suppressed by AG490, a STAT3 inhibitor, not other inhibitors (p < 0.05) (Fig. 9A) . To present the morphology of AQP4 protein in cultured astrocytes, we highlighted the nuclei by DAPI staining. Different from the polarized distribution in brain tissues, expression of AQP4 protein was found homogeneously distributed in the cytoplasm of cultured astrocytes. Both Western blot and immunofluorescence revealed that rhG-CSF up-regulated AQP4 protein expression in astrocytes (p < 0.05), which was inhibited only by U0126, an ERK inhibitor (p < 0.05) (Fig. 9B-I ).
DISCUSSION
Limited researches on G-CSF and ICH reveal positive results, including reduction of perihematomal brain edema, BBB permeability and numbers of apoptotic cells with improvement of neurological functions (Park et al., 2005; Zhang et al., 2009 ). However, the effects were only focused on isolated time points and lack of dynamic and continuous observation. To date, the involved mechanisms remain unknown. In the present study, we put emphasis on perihematomal tissue injuries, the key pathologic damage in ICH and we chose the three time points: 1, 3 and 7 days after ICH, which are just in phases of injuries starting, aggravation and elimination respectively. We found that G-CSF significantly alleviated perihematomal brain edema, BBB permeability, apoptosis and death of neural cells with improvement of neurological functions at all chosen time points. These findings are consistent with previous studies, suggesting protective effects of G-CSF on perihematomal tissue injuries. We further investigated the involved mechanisms: whether G-CSF elicited its protective effects by regulating the expression of VEGF and AQP4. G-CSF is closely related with VEGF. It was reported that administration of G-CSF can increase VEGF and its receptors in normal rat brain and cultured cells (Ohki et al., 2005; Jung et al., 2006) . We observed the similar results in normal mice and first found intraperitoneal injection of G-CSF was able to up-regulate perihematomal VEGF protein expression. Furthermore, Fig. 4 . Effects of G-CSF on ICH in AQP4 +/+ and AQP4 À/À mice. RhG-CSF injected intraperitoneally significantly reduced perihematomal brain water content, brain specific gravity, EB extravasation amount, neurological scores and numbers of TUNEL staining cells as well as increased Nissl staining cells at 1, 3 and 7 days after ICH in both types of mice (n = 6, we demonstrated that G-CSF only increased Flk-1, but not Flt-1 both in normal striatum and surrounding the hematoma at any chosen time point. So we speculated that VEGF's protective effects mainly relied on Flk-1 and Flk-1 specific inhibitor SU5416 was selected to examine the hypothesis. In the current study, intracerebroventricular injection of SU5416 attenuated the effects of G-CSF on alleviating neurological deficits, perihematomal brain edema, neuronal death and apoptosis, only the G-CSF's effects on BBB permeability remaining unchanged. This indicates VEGF may mediate G-CSF's protective effects on perihematomal tissue injuries. VEGF is an important neuroprotective factor. It has been proven that VEGF can reduce neuronal death and apoptosis in various CNS diseases, including cerebral ischemia and ICH (Lee et al., 2007; Feng et al., 2010) . We got similar results by TUNEL and Nissl staining and positive cell counting. The mechanisms include downregulation of caspase-3, pro-apoptotic and neurotoxic proteins such as Bax and Ab1-42, as well as up-regulation of anti-apoptotic and neurotrophic proteins such as Bcl-2, Bcl-XL and pigment epithelial-derived factor (Lee et al., 2007; Feng et al., 2010; Sanchez et al., 2010) . It is still controversial how VEGF acts on brain edema and BBB permeability. Taking cerebral ischemic models for example, different studies showed various effects of VEGF that it can reduce, not aggravate, or worsen it (Harrigan et al., 2003; Kaya et al., 2005; Bates, 2010) . VEGF can increase BBB permeability and ultrastructures in normal state (Rite et al., 2007) , but may counteract with the damage effects by protecting endothelial cells in case of pathological damage . So VEGF is a factor known to increase BBB permeability but here SU5416 blocked some of the beneficial effects of G-CSF and worsened BBB permeability, suggesting that the direct BBB effects of VEGF in this model are outweighed by parenchymal effects which may indirectly affect the BBB. Our recent work revealed VEGF reduced brain edema surrounding hematoma but had no influence on BBB permeability following ICH (Chu et al., 2013) . This is consistent with the current results. However, SU5416 attenuated but not counteracted G-CSF's protective effects, suggesting there may be other protective mechanisms involved.
Although both G-CSF and AQP4 play important roles in brain edema, there has been no direct research explaining their relationship. We first demonstrated that intraperitoneal injection of G-CSF significantly up-regulated AQP4 protein expression at normal striatum as well as surrounding the hematoma. Since VEGF was also reported to increase AQP4 expression (Rite et al., 2008) and G-CSF up-regulated VEGF in our study, did the above effects of VEGF have something to do with up-regulation of AQP4 by increased endogenous VEGF? Furthermore, we found SU5416 was not able to block the up-regulation of AQP4 by G-CSF, indicating AQP4 was not increased by endogenous VEGF and they play independent roles in (Fig. 4E ). RhG-CSF had no effect on TUNEL staining in normal mice. There were more apoptotic cells in AQP4 À/À mice than AQP4 +/+ mice in ICH and ICH plus G-CSF groups. RhG-CSF decreased perihematomal TUNEL-positive cells in both AQP4 +/+ and AQP4 À/À mice, which was not influenced by SU5416. (A) Groups of control, control plus G-CSF and sham operation at 3 days. (B) Groups of ICH, ICH plus G-CSF and ICH plus G-CSF plus SU5416 at 1, 3 and 7 days after ICH. Scale bar = 50 lm.
G-CSF's effects on ICH. These findings provide the possibility of AQP4 being involved in exogenous G-CSF's effects on ICH. We demonstrated that AQP4 À/À mice had more severe perihematomal tissue injuries than AQP4 +/+ mice after ICH, which was similar to our previous study (Tang et al., 2010) . Meanwhile, G-CSF induced protective effects in both AQP4
+/+ and AQP4
À/À mice after ICH, but injuries in AQP4 À/À mice were still more severe than AQP4 +/+ mice. To investigate whether these effects of G-CSF had something to do with AQP4, we studied the interactions between G-CSF injection and presence of AQP4 gene by a two-way ANOVA with replication. We found interactions between G-CSF administration and presence of AQP4 gene, indicating that AQP4 is also involved in G-CSF's such effects. (Fig. 4F) . Injection of rhG-CSF had no effect on Nissl staining in normal mice. At the three time points, marked neuron loss perihematoma was found in AQP4 À/À mice when compared to AQP4 +/+ mice. Besides, rhG-CSF increased perihematomal Nissl staining cells in both AQP4
+/+ and AQP4 À/À mice, which was not influenced by SU5416. (A) Groups of control, control plus G-CSF and sham operation at 3 days. (B) Groups of ICH, ICH plus G-CSF and ICH plus G-CSF plus SU5416 at 1, 3 and 7 days after ICH. Asterisks represent the hematoma zones. Scale bar = 50 lm.
AQP4 plays essential roles in the formation and resolution of brain edema as well as has more effects on glial cells. It has been proven that AQP4 is involved in formation of cytotoxic edema and elimination of vasogenic edema (Verkman, 2009 ). Vasogenic edema caused by BBB disruption starts several hours after ICH and peaks at several days with secondary cellular injury giving rise to cytotoxic edema. Among the multiple types of edema presented after ICH, the main form is probably vasogenic (Xi et al., 2006; Reggio and Loretol, 2010) . The time points chosen in our study are just in phases of vasogenic edema formation, peak, and elimination after ICH. Therefore, the brain edema reduced by G-CSF in the three phases of ICH partially results from AQP4 up-regulation to enhance elimination of vasogenic edema. Moreover, AQP4 is highly concentrated in astrocyte foot processes surrounding capillaries, which is an important target for BBB integrity maintenance. Previous studies highlighted the importance of AQP4 in maintaining integrity of BBB in development and adult individuals (Nico et al., 2001; Zhou et al., 2008) . In our previous study, electron micrographs showed that expression of AQP4 suppressed the perivascular space widening and endothelial cell swelling after ICH when compared with the AQP4 À/À mice group (Tang et al., 2010) . Therefore, we speculate that increase of AQP4 expression after ICH can maintain BBB integrity by protecting astrocytes and tight junction. AQP4 was reported to regulate the level of glutamate, a neurotoxic factor, to inhibit neuronal death (Li et al., 2006; Zeng et al., 2007) . Meanwhile, reactive oxygen species (ROS) may be involved in AQP4's effect of regulating apoptosis (Esposito et al., 2008) . In addition, our recent study showed AQP4 was involved in VEGF's protective effects on ICH (Chu et al., 2013) . Put together with the above findings and results of our current study, effects of G-CSF to alleviate perihematomal tissue injuries are AQP4 dependent.
It has been proven that biological effects of G-CSF mainly rely on activation of JAK/STAT pathway after combination with its receptor (Harada et al., 2005) . Besides, G-CSF can also activate MAPK and PI3K/Akt pathways (Huang et al., 2007; Carvalho et al., 2011) . In our work, we demonstrated that G-CSF increased p-ERK and p-STAT3 in cultured astrocytes, implying G-CSF activated ERK and JAK/STAT3 pathways. Meanwhile, the changing trend of VEGF by G-CSF was consistent with p-STAT3 and STAT3 inhibitor AG490 prevented VEGF up-regulation. Previous researches indicated VEGF was up-regulated by activation of JAK/ STAT3 pathway in CNS under physiological and pathological states (Loeffler et al., 2005; Jung et al., 2006) . So it is possible that G-CSF up-regulates VEGF expression due to JAK/STAT3 pathway activation. Similarly, AQP4 protein and p-ERK were increased and peaked at the same time course by G-CSF administration, and this phenomenon was suppressed by an ERK inhibitor, U0126. Besides, the inhibitors of ERK and p38-MAPK were reported to suppress AQP4 up-regulation induced by manganese-treated or oxygenglucose deprivation and recovery (Rao et al., 2010; Qi et al., 2011) . Therefore, it is not hard to speculate that G-CSF increases AQP4 expression via ERK pathway.
CONCLUSION
We demonstrate that G-CSF has protective effects on perihematomal tissue injuries following ICH. Besides, we also find that the effects of G-CSF to reduce perihematomal brain edema, neuronal death and apoptosis, and neurological deficits are closely related with VEGF and AQP4 up-regulation, while G-CSF's effect on alleviating BBB leakage is only AQP4 dependent. In addition, our study reveals that VEGF and AQP4 up-regulation by G-CSF maybe results from the activation of STAT3 and ERK pathways respectively. The current study provides triple targets to treatment of perihematomal tissue injuries following ICH, which can present new insights to drugs development.
